SCHEMBL221735

SCHEMBL221735

Cc1cccc(Cc2nc3ccccc3n2C(C=O)N2CCOCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 2/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 4/20 0.43
ALDH1A2 O94788 3/20 0.42
ALDH1A1 P00352 3/20 0.42
ALDH2 P05091 3/20 0.42
ALDH3A1 P30838 3/20 0.42
ALDH1A3 P47895 3/20 0.42
PIK3CB P42338 5/20 0.40
PIK3CD O00329 2/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CG P48736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221734 0.73 CYP3A4 (0.57) TP53MEN1KMT2ANPSR1GAA
SCHEMBL22055666 0.63 LMNA (0.49) MEN1KMT2APIK3CBPIK3CDPIK3CA
SCHEMBL8568250 0.63 PIK3CB (0.45) PIK3CBPIK3CDPIK3CAPIK3CG
SCHEMBL15723845 0.62 KDM4E (0.58) MEN1KMT2ANPSR1GAAMAPT
SCHEMBL178443 0.60 NCF1 (0.66) MAPTALDH1A1
SCHEMBL14826491 0.59 ALDH1A1 (0.70) TP53MEN1KMT2ANPSR1MAPT
SCHEMBL9431028 0.58 TNF (0.74) TP53MEN1KMT2ANPSR1TSHR
SCHEMBL632013 0.58 MMP8 (0.45) MEN1KMT2ANPSR1MAPK1ALDH1A1
SCHEMBL12021982 0.58 HRH3 (0.73) NPSR1TSHRMAPT
SCHEMBL22040866 0.58 L3MBTL1 (0.53) MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9132294-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin AVON PRODUCTS, INC. (US) 2015-09-15 US disclosed
EP-2588593-A2 COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN Avon Products, Inc. (US) 2013-05-08 EP disclosed
WO-2012005876-A2 COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN AVON PRODUCTS, INC. (US) 2012-01-12 WO disclosed
US-20120003332-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin AVON PRODUCTS, INC. (US) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120003332-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin MAG, MFAP1, CUTA TP53 4379/4885MEN1 1939/4885KMT2A 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.